{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:28:53Z","timestamp":1790234933421,"version":"4.1.0"},"reference-count":85,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4\/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.<\/jats:p>","DOI":"10.3390\/medicina55080490","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T11:11:00Z","timestamp":1565867460000},"page":"490","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Malignant Pleural Effusion and Its Current Management: A Review"],"prefix":"10.3390","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3027-8164","authenticated-orcid":false,"given":"Kristijan","family":"Skok","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Maribor, Institute of Biomedical Sciences, Taborska Ulica 8, SI-2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaja","family":"Hladnik","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Maribor, Taborska Ulica 8, SI-2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Grm","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Maribor, Taborska Ulica 8, SI-2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Crnjac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Maribor, Taborska Ulica 8, SI-2000 Maribor, Slovenia"},{"name":"Department of thoracic surgery, University Medical Centre Maribor, Ljubljanska 5, SI-2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion: From bench to bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/ejcts\/ezy258","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"55","author":"Bibby","year":"2019","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of Malignant Pleural Effusions. An Official ATS\/STS\/STR Clinical Practice Guideline","volume":"198","author":"Sterman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/CMAR.S95663","article-title":"Management of malignant pleural effusion: Challenges and solutions","volume":"9","author":"Penz","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.1503\/cmaj.170420","article-title":"Evaluation of the patient with pleural effusion","volume":"190","author":"Beaudoin","year":"2018","journal-title":"Can. Med Assoc. J."},{"key":"ref_6","first-page":"33","article-title":"Physiology of the pleural space","volume":"7","author":"Charalampidis","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1357-2725(03)00242-5","article-title":"The mesothelial cell","volume":"36","author":"Mutsaers","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMra1403503","article-title":"Pleural disease","volume":"378","author":"Ingelfinger","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccm.2012.11.006","article-title":"The Light Criteria: The Beginning and Why they are Useful 40 Years Later","volume":"34","author":"Light","year":"2013","journal-title":"Clin. Chest Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CPM.0b013e318285ba37","article-title":"The Art of Pleural Fluid Analysis","volume":"20","author":"Sahn","year":"2013","journal-title":"Clin. Pulm. Med."},{"key":"ref_11","first-page":"15","article-title":"Biomarkers in routine diagnosis of pleural effusions","volume":"87","author":"Rozman","year":"2018","journal-title":"Zdr. Vestn."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1874306401408010014","article-title":"Da Pleural Cholesterol to the Diagnosis of Exudative Effusion","volume":"8","author":"Rufino","year":"2014","journal-title":"Open Respir. Med. J."},{"key":"ref_13","first-page":"BC14","article-title":"Significance of Total Protein, Albumin, Globulin, Serum Effusion Albumin Gradient and LDH in the Differential Diagnosis of Pleural Effusion Secondary to Tuberculosis and Cancer","volume":"10","author":"Samanta","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MCP.0b013e32836022dc","article-title":"Identifying transudates misclassified by Light\u2019s criteria","volume":"19","author":"Porcel","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00408-017-0032-3","article-title":"Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters","volume":"195","year":"2017","journal-title":"Lung"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thorsurg.2012.10.008","article-title":"Anatomy and Pathophysiology of the Pleura and Pleural Space","volume":"23","author":"Yalcin","year":"2013","journal-title":"Thorac. Surg. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","article-title":"Malignant pleural effusion: Tumor-host interactions unleashed","volume":"186","author":"Stathopoulos","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15205","DOI":"10.1038\/ncomms15205","article-title":"Mutant KRAS promotes malignant pleural effusion formation","volume":"8","author":"Agalioti","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_19","first-page":"8019","article-title":"The role of VEGF in the diagnosis and treatment of Malignant pleural effusion in patients with non-small cell lung cancer (review)","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1172\/JCI79840","article-title":"Mast cells mediate malignant pleural effusion formation","volume":"125","author":"Giannou","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.path.2018.05.003","article-title":"Updates in Effusion Cytology","volume":"11","author":"Lepus","year":"2018","journal-title":"Surg. Pathol. Clin."},{"key":"ref_22","first-page":"1009","article-title":"Switching off malignant pleural effusion formation-fantasy or future?","volume":"7","author":"Spella","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_23","first-page":"83","article-title":"Pomen mutacije gena receptorja za epidermalni rastni dejavnik za zdravljenje nedrobnoceli\u010dnega raka plju\u010d","volume":"15","year":"2011","journal-title":"Onkologija"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00408-017-0050-1","article-title":"Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion","volume":"195","author":"Porcel","year":"2017","journal-title":"Lung"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score","volume":"69","author":"Clive","year":"2014","journal-title":"Thorax"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: Current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2017.00193","article-title":"Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification","volume":"7","author":"Inamura","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Network","year":"2014","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/resp.12496","article-title":"Clinical features and survival of lung cancer patients with pleural effusions","volume":"20","author":"Porcel","year":"2015","journal-title":"Respirology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MCP.0000000000000264","article-title":"Malignant pleural effusions because of lung cancer","volume":"22","author":"Porcel","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/1754-9485.12727","article-title":"Procedure-related tumour seeding in lung cancer with malignant pleural effusion: Radiological features and outcomes","volume":"62","author":"Cattapan","year":"2018","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_33","first-page":"1169","article-title":"Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma the effect of preanalytical factors","volume":"14","author":"Carter","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1148\/radiol.2015142388","article-title":"Minimal Pleural Effusion in Small Cell Lung Cancer: Proportion, Mechanisms, and Prognostic Effect","volume":"278","author":"Ryu","year":"2015","journal-title":"Radiology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/raon-2017-0008","article-title":"Cancer burden in Slovenia with the time trends analysis","volume":"51","author":"Zadnik","year":"2017","journal-title":"Radiol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent Advances in the Treatment of Breast Cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/dc.23607","article-title":"Metastatic Breast Carcinoma in Pleural Fluid: Correlation of Receptor and HER2 status with the primary carcinoma\u2014A Pilot study","volume":"44","author":"Francis","year":"2016","journal-title":"Diagn. Cytopathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crad.2014.08.015","article-title":"Metastatic patterns of breast cancer subtypes: What radiologists should know in the era of personalized cancer medicine","volume":"70","author":"Chikarmane","year":"2015","journal-title":"Clin. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.12659\/AJCR.889249","article-title":"Malignant pleural effusion in breast cancer 12 years after mastectomy that was successfully treated with endocrine therapy","volume":"14","author":"Shinohara","year":"2013","journal-title":"Am. J. Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/AJCPYO5FSV3UPEXS","article-title":"From Breast Cancer Subtypes Predispose the Site of Distant Metastases","volume":"143","author":"Soni","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"55550","DOI":"10.18632\/oncotarget.15548","article-title":"Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy","volume":"8","author":"Schrijver","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","first-page":"2673","article-title":"Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer","volume":"18","author":"Tavares","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_45","unstructured":"Logar, H.B.Z., Smrkolj, \u0160., and Merlo, S. (2016). Smernice za Obravnavo Bolnic z Rakom Jaj\u010dnikov, Jajcevodov in s Primarnim Peritonealnim Seroznim Rakom, Onkolo\u0161ki in\u0161titut Ljubljana."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2016.06.013","article-title":"FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited","volume":"142","author":"Ataseven","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1440-1843.2012.02177.x","article-title":"Clinical implications of pleural effusions in ovarian cancer","volume":"17","author":"Porcel","year":"2012","journal-title":"Respirology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/IGC.0000000000001268","article-title":"Incidental Thoracic Findings on Routine Computed Tomography in Epithelial Ovarian Cancer","volume":"28","author":"Treacy","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_50","unstructured":"Novakovi\u0107, B.J. (2019). Smernice za Obravnavo Bolnikov z Malignimi Limfomi, Onkolo\u0161ki in\u0161titut Ljubljana."},{"key":"ref_51","first-page":"8092","article-title":"Diagnostic value of medical thoracoscopy in malignant pleural effusion induced by non-Hodgkin\u2019s lymphoma","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/1759-7714.12256","article-title":"Rare case of primary pleural lymphoma presenting with pleural effusion","volume":"7","author":"Sun","year":"2016","journal-title":"Thorac. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/LBR.0000000000000270","article-title":"Pleural lymphoma","volume":"23","author":"Choy","year":"2016","journal-title":"J. Bronchol. Interv. Pulmonol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/OTT.S167392","article-title":"Primary effusion lymphoma: Current perspectives","volume":"11","author":"Narkhede","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1378\/chest.125.4.1546","article-title":"Pleural effusions in hematologic malignancies","volume":"125","author":"Alexandrakis","year":"2004","journal-title":"Chest"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1309\/AJCP6LXA2LKFZAMC","article-title":"Malignant effusions correlate with poorer prognosis in patients with diffuse large B-cell Lymphoma","volume":"143","author":"Chen","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.6016\/ZdravVestn.2836","article-title":"Hipertermi\u010dna intraperitonealna kemoterapija","volume":"88","author":"Skok","year":"2019","journal-title":"Slov. Med. J."},{"key":"ref_58","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"Clarke","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality \u2014 United States, 1999\u20132015","volume":"66","author":"Mazurek","year":"2017","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.21037\/jtd.2017.10.88","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: A literature review","volume":"10","author":"Bruno","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0004563217741145","article-title":"Biomarkers in mesothelioma","volume":"55","author":"Arnold","year":"2018","journal-title":"Ann. Clin. Biochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/resp.12874","article-title":"Malignant pleural fluid from mesothelioma has potent biological activities","volume":"22","author":"Cheah","year":"2016","journal-title":"Respirology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_65","first-page":"235","article-title":"Malignant pleural effusion: Pathogenesis, diagnosis, and management","volume":"8","author":"Geltner","year":"2015","journal-title":"Memo Mag. Eur. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S1111","DOI":"10.21037\/jtd.2017.07.79","article-title":"Diagnosis and management of malignant pleural effusions: State of the art in 2017","volume":"9","author":"Desai","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.14-0013","article-title":"Derivation and Validation of a CT Scan Scoring System for Discriminating Malignant From Benign Pleural Effusions","volume":"147","author":"Porcel","year":"2015","journal-title":"Chest"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.09-0641","article-title":"Prospective Study To Determine the Volume of Pleural Fluid Required To Diagnose Malignancy","volume":"137","author":"Swiderek","year":"2010","journal-title":"Chest"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1753466618808660","DOI":"10.1177\/1753466618808660","article-title":"Biomarkers in the diagnosis of pleural diseases: A 2018 update","volume":"12","author":"Porcel","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.trsl.2015.04.006","article-title":"Diagnostic value of tumor antigens in malignant pleural effusion: A meta-analysis","volume":"166","author":"Agrawal","year":"2015","journal-title":"Transl. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753466618785098","article-title":"Contemporary best practice in the management of malignant pleural effusion","volume":"12","author":"Koegelenberg","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1515\/raon-2015-0002","article-title":"Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: A randomized control study","volume":"49","author":"Hojski","year":"2015","journal-title":"Radiol. Oncol."},{"key":"ref_73","first-page":"272","article-title":"Kirur\u0161ke mo\u017enosti zdravljenja malignih plevralnih izlivov karcinoma dojke","volume":"79","author":"Crnjac","year":"2010","journal-title":"Zdr. Vestn."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.9778\/cmajo.20170163","article-title":"Clinical predictors of successful and earlier pleurodesis with a tunnelled pleural catheter in malignant pleural effusion: A cohort study","volume":"6","author":"Li","year":"2018","journal-title":"CMAJ Open"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of malignant pleural effusions: The case for localized immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/IJPC.IJPC_2_17","article-title":"Sibli Prognostic Factors of 30-day Survival of Patients with Malignant Pleural Effusion","volume":"23","author":"Amin","year":"2017","journal-title":"Indian J. Palliat Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ejcts.2004.03.010","article-title":"Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma","volume":"26","author":"Crnjac","year":"2004","journal-title":"Eur. J. Cardio Thorac. Surg."},{"key":"ref_79","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"244","DOI":"10.21037\/atm.2017.06.60","article-title":"Diagnosis and prognosis-review of biomarkers for mesothelioma","volume":"5","author":"Sun","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S1003","DOI":"10.21037\/jtd.2018.04.31","article-title":"Biomarkers in malignant pleural mesothelioma: Current status and future directions","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"i61","DOI":"10.1136\/thx.2010.137026","article-title":"Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010","volume":"65","author":"Havelock","year":"2010","journal-title":"Thorax"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/thoraxjnl-2014-206114","article-title":"Thoracentesis outcomes: A 12-year experience","volume":"70","author":"Ault","year":"2015","journal-title":"Thorax"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/8\/490\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:11:26Z","timestamp":1760188286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/8\/490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":85,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["medicina55080490"],"URL":"https:\/\/doi.org\/10.3390\/medicina55080490","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}